About Sara Sofia Deville
Scientist specialized in 3D biology with hands-on experience in high-throughput screening using physiologically relevant models. During my PhD, I focused on developing and optimizing 3D cell culture assays (such as spheroids, organoids, and 3D colony formation assays) for use in high-throughput settings, gaining strong expertise in assay design and imaging. In my industry role, I contributed to the automation of complex 3D biology workflows, supporting decision-making through advanced imaging and AI-based image analysis. I’ve worked extensively with iPSCs, adult stem cells, and various 3D assay formats, driving innovation at the interface of cell biology, automation, and data science.
Organoids, chips or both?
Nature of your workplace/organisation
Your research model interests
Research study area
Influencer Of
Popular Content
Topics
Channels contributed to:
Free Open Access Organoid papers. Learning, webinars & guides Free Open Access Chip papers. Exclusive FREE talks for FULL Community membersRooms participated in:
WORCs 4 me! Introduce yourself, find an expert/start a chat/post a paper/ask a question? Cardio vascular /Circulatory Gastro intestinal Bladder and urinary systemRecent Discussions
3D Bioprinting in Toxicology NAMs
Hi everyone,I’m curious about the community’s view on 3D bioprinting in the context of NAMs.
Do you think bioprinting realistically adds value compared with other 3D systems, such as organoids or organ-on-a-chip models? Or is it still too complex and low-throughput for routine toxicology and screening?
I’d be interested to hear whether anyone here is actually using it in a NAM pipeline and whether it has been worth the investment.
Recent Comments
More pediatric 3D organoid models are urgently needed in oncology to understand childhood cancers better and give every child the best chance at effective, life-saving treatments.
Many parents-to-be chose to undergo Non-Invasive Prenatal Testing (NIPT), not only to screen for common trisomies (such as 21, 18, and 13), but also for 22q11.2 deletion syndrome.
But why is it important to include 22q11.2 deletion in prenatal screening?
22q11.2 deletion syndrome (also known as DiGeorge syndrome) is one of the most common microdeletion syndromes. It can lead to a wide range of health issues, including congenital heart defects, immune deficiencies, developmental delays, and neuropsychiatric disorders such as schizophrenia.
This recent study sheds new light on the neurological implications of this deletion. Using brain organoids derived from patients with 22q11.2 deletion syndrome, researchers discovered an aberrant pace of cortical neuron development, offering insights into the biological mechanisms potentially underpinning schizophrenia.